Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

View basket
☰

Buspar

Buspar
In stock
5mg · 10mg
from 31,47 £
Strength
Pack size — the bigger the pack, the cheaper the tablet
57,56 £47,96 £
0,53 £ per tablet

In brief

  • Buspar (buspirone) is a prescription-only medicine in the UK and should be obtained from a pharmacy on prescription.
  • Buspirone is used principally for generalised anxiety disorder (GAD) and as an adjunct in some depressive disorders; it is a non‑benzodiazepine anxiolytic that acts mainly as a partial agonist at 5‑HT1A (serotonin) receptors with additional dopaminergic effects, producing anxiolysis without the sedative or dependence risks of benzodiazepines.
  • The usual adult dose starts at 5 mg two or three times daily, with a typical maintenance range of 15–30 mg daily given in two or three divided doses; dose may be increased every 2–3 days up to a maximum of 45 mg/day under medical supervision.
  • Buspar is administered orally as tablets (common strengths: 5 mg and 10 mg).
  • Therapeutic onset is not immediate—maximum benefit often requires 2–4 weeks of regular dosing, though some patients may notice earlier improvement.
  • Each dose has a relatively short pharmacological duration, so symptomatic coverage is achieved by taking it two to three times daily; individual effects typically last several hours after each dose (clinical dosing schedules aim to maintain steady symptom control throughout the day).
  • Avoid or limit alcohol while taking buspirone; combining alcohol may increase dizziness, drowsiness and other CNS side effects and can impair judgement and coordination.
  • The most common side effects include dizziness (also frequently reported: headache, nausea, nervousness, lightheadedness, restlessness, insomnia and dry mouth); most are mild and transient.
  • Would you like to try Buspar without a prescription?

Basic Buspar information

  • INN (international nonproprietary name): buspirone.
  • Brand names available in the United Kingdom: generic buspirone tablets (e.g. Teva, Mylan); Buspar is the original brand.
  • ATC code: N05BE01.
  • Forms and dosages: Tablets 5 mg and 10 mg; typically blister packs.
  • Manufacturers in the United Kingdom: generic manufacturers such as Teva, Mylan and Sandoz.
  • Registration status in the United Kingdom: prescription only and licensed for anxiety; prescribers should consult current UK product licences for specifics.
  • OTC / Rx classification: Prescription (Rx‑only) in the United Kingdom.

Safety, warnings and patient protection (UK focus)

High‑risk groups (elderly, pregnancy, chronic illness)

What should worry me first when starting buspirone?

Confirm whether the patient has a valid prescription, because buspirone is prescription only (POM) in the UK.

Check the MHRA safety alerts and product‑specific bulletins before initiation.

Obtain informed consent and document the discussion before starting treatment.

Absolute contraindications include known hypersensitivity to buspirone or excipients.

Avoid use in patients concurrently taking strong CYP3A4 inhibitors unless a specialist has advised otherwise, because such medicines can sharply increase buspirone exposure.

Exercise caution and start at the lower end of dosing in elderly patients due to increased sensitivity to central nervous system effects.

Reduce initial dose and slow titration in moderate to severe hepatic or renal impairment and monitor for increased adverse effects.

Buspirone is not recommended for children under 18, as efficacy and safety are not established in this age group.

Pregnancy and breastfeeding: data are limited, so discuss benefits and risks with the obstetric or specialist team and consider alternatives with clearer pregnancy safety data where appropriate.

  • Rapid screening checklist
  • Current medicines (prescribed, OTC, herbal and recreational).
  • Known liver or kidney disease.
  • Pregnancy, planning pregnancy or breastfeeding.
  • History of substance misuse or dependence.
  • Allergy to psychotropic medicines or any tablet excipient.
  • Pharmacy/clinician checklist
  • Document baseline medicines and relevant comorbidities in the clinical record.
  • Record baseline liver and renal function where impairment is suspected or for high doses.
  • Advise patients about common side effects and the delayed onset of benefit.
  • Encourage reporting of adverse effects to the MHRA Yellow Card scheme.

Interaction with activities (driving, workplace safety under UK law)

Will buspirone affect my ability to drive or work safely?

Buspirone is generally described as non‑sedating but common side effects include dizziness, lightheadedness and drowsiness.

UK driving law requires notification to the DVLA only when a condition or medication causes impaired driving; clinicians should explain that the legal obligation depends on actual impairment.

Advise patients not to drive or operate heavy machinery until they know how buspirone affects them.

Employers and staff in safety‑critical roles should be advised to consult occupational health about suitability for work in transport, healthcare, construction or similar posts.

For shift workers or those in safety‑sensitive roles, recommend a trial period at home with daytime monitoring for side effects and written advice from the prescriber or pharmacist.

Advise against alcohol or other sedatives while taking buspirone because concomitant use increases dizziness and cognitive impairment risk.

  • Workplace actions checklist
  • Begin a trial period at home before returning to safety‑critical duties.
  • Report any new dizziness, drowsiness or concentration problems to employer and clinician immediately.
  • Arrange occupational health referral for formal fitness‑for‑work advice if needed.
  • Provide written advice from prescriber or pharmacist for employer records.

Q — Can I drive after taking it in the UK?

A — Not until you know how it affects you.

If you experience dizziness or drowsiness, do not drive.

Follow DVLA guidance and consult your prescriber if in doubt.

Usage basics

INN, brand names available in the UK

What names will I see on a prescription or pack?

INN
buspirone.
ATC code
N05BE01 (classifies buspirone as a non‑benzodiazepine anxiolytic).
Common forms
Tablets in strengths 5 mg and 10 mg.

Legal classification (POM, P, GSL)

How do I obtain buspirone in the UK?

  • Buspirone is prescription-only (POM) across the UK; supplies require a valid NHS or private prescription.
  • Prescription steps: see your GP or a psychiatrist for assessment and a prescription.
  • Private psychiatrists or private clinics can issue a private Rx that community pharmacies will dispense.
  • NHS electronic prescriptions can be issued and redeemed at community pharmacies.
  • Pharmacists will perform counselling and required safety checks at dispensing.

Dosing guide

Standard regimens (NHS guidelines)

How is buspirone usually dosed for adults?

Typical adult initiation is 5 mg two or three times daily with maintenance commonly 15–30 mg daily in two or three divided doses.

The maximum daily dose is 45 mg, but dose adjustments depend on clinical response and tolerability.

Titrate cautiously by approximately 5 mg every 2–3 days if required.

Onset of therapeutic effect can take 2–4 weeks, so buspirone is not suitable as a PRN or rescue anxiolytic.

Step Suggested dose Usual dosing windows
Initiation 5 mg two or three times daily Morning, midday, evening
Titration Increase by ~5 mg every 2–3 days as needed Morning, midday, evening (divided doses)
Typical maintenance 15–30 mg daily in two or three divided doses Morning, midday, evening
Maximum Up to 45 mg daily Divided doses across the day

Adjustments for comorbidities

How should dosing change for older patients or those with organ impairment?

  • Start at a reduced dose and titrate more slowly in elderly patients because of greater CNS sensitivity and fall risk.
  • Reduce dose and monitor in significant hepatic or renal impairment due to reduced clearance.
  • Avoid concurrent MAO inhibitors and use caution with strong CYP3A4 inhibitors that can raise buspirone levels.
  • Ensure all medicines are documented and reviewed by a pharmacist before dose increases.

Q — what if I miss a dose?

A — Take as soon as you remember unless the next dose is due soon.

Do not double doses to make up for a missed one.

If unsure, contact your pharmacist or prescriber for advice.

Interaction chart (food, drink and medicines)

Food and drinks

What should I avoid eating or drinking while on buspirone?

  • Avoid alcohol while taking buspirone because it can increase dizziness and sedation.
  • Moderate caffeine intake as it can exacerbate nervousness or insomnia in some patients.
  • Grapefruit and large quantities of grapefruit juice should be avoided or limited because grapefruit can inhibit CYP3A4 and raise buspirone exposure.
  • Take with or without food depending on tolerability; taking with food may reduce nausea for some patients.

Common drug conflicts

Which medicines are most important to check?

Interacting drug class Mechanism Action
Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, some macrolides) Reduce hepatic metabolism of buspirone Avoid or consult specialist; monitor closely
Monoamine oxidase inhibitors (MAOIs) Potential for severe reactions when combined Relative contraindication; do not co‑prescribe
Sedatives, hypnotics, alcohol Additive CNS depression and impaired coordination Avoid concurrent use and counsel patient
Antidepressants (SSRIs, SNRIs) Adjunctive use is reported; monitor clinical response and interactions Use with monitoring; document rationale
  • Encourage patients and clinicians to report suspected interactions or adverse reactions via the MHRA Yellow Card scheme.
  • Ask the pharmacist to screen all new prescriptions and OTC medicines for interactions before dispensing.

Legal status and availability in the UK

In our online pharmacy, Buspar is available without a prescription, with discreet delivery to the United Kingdom in 5‑14 days.

Mechanism and pharmacology

Simplified explanation

How does buspirone work?

Buspirone is a non‑benzodiazepine anxiolytic that principally acts as a partial agonist at 5‑HT1A receptors, influencing serotonergic and dopaminergic neurotransmission.

Unlike benzodiazepines, buspirone has minimal anticonvulsant or muscle‑relaxant effects and a low dependence potential.

Its pharmacology explains the delayed onset of effect and the limited role in acute panic or rescue therapy.

Clinical terms

Partial agonist
Activates receptors (5‑HT1A) but produces a smaller response than a full agonist, modulating rather than maximally stimulating serotonin signalling.
CYP3A4 metabolism
Buspirone is metabolised via CYP3A4; inhibitors of this enzyme can raise blood levels and increase side effects.
Half‑life implications
Pharmacokinetics support twice or thrice daily dosing and explain why steady clinical benefit takes days to weeks.
Absence of GABAergic sedation
Because buspirone does not act on GABA receptors, it lacks the marked sedation and dependence risk seen with benzodiazepines.
  • Practical expectation: delayed benefit, fewer withdrawal issues compared with benzodiazepines.

Indications and off‑label uses

MHRA‑approved uses

What is buspirone licensed for in the UK?

  • Primary approved indication is generalised anxiety disorder (GAD).

Off‑label practices in NHS and private care

How do clinicians sometimes use buspirone off‑label?

  • Off‑label uses include augmentation in depression, aiding benzodiazepine taper, adjunctive treatment in PMDD and selected anxiety‑spectrum adjunct roles.
  • Off‑label prescribing requires a documented rationale, informed patient consent and a clear monitoring plan.
  • Buspirone is not recommended for panic disorder or as rescue medication for acute anxiety episodes.
  • Clinician checklist for off‑label use
  • Summarise the supporting evidence and alternative options.
  • Document informed consent and expected outcomes.
  • Set monitoring milestones and a follow‑up plan.

Alternatives matrix

NHS prescribing alternatives (comparison table)

Option Onset Dependence risk Sedation NHS initiation pathway Suitability for substance misuse history
SSRIs (sertraline, escitalopram) 2–4 weeks Low Variable GP or specialist initiation, monitoring Generally suitable
SNRIs (venlafaxine, duloxetine) 2–4 weeks Low Variable Specialist or GP initiation Generally suitable
Benzodiazepines (diazepam, lorazepam) Rapid (minutes to hours) High High Short‑term prescribing only with clear plan Typically unsuitable
Hydroxyzine Rapid Low High (sedating) GP initiation for short term use May be suitable but sedating
Buspirone 2–4 weeks Low Low GP or psychiatrist initiation, titration required Preferred option in substance misuse history

Pros and cons checklist

  • Buspirone — pros: non‑habit forming, minimal sedation, suitable where dependence is a concern.
  • Cons: delayed onset, not effective as rescue for acute panic, requires dose adjustments in liver/kidney disease.
  • SSRIs — pros: strong evidence for long‑term anxiety management, low dependence.
  • Cons: sexual side effects, GI upset, monitoring for interactions.
  • Benzodiazepines — pros: rapid relief for severe acute anxiety.
  • Cons: dependence, sedation, not recommended for long‑term use.

Common questions

  • Q: How long until I feel better?
  • A: Often 2–4 weeks; full benefit may take longer.
  • Steps if no improvement:
  • — Check adherence and correct dosing.
  • — Review concomitant medicines and interactions.
  • — Consider dose adjustment or adjunct therapy with specialist input.
  • Q: Is it addictive?
  • A: Not typically; buspirone is not associated with the dependence profile of benzodiazepines.
  • Q: Can I take it with antidepressants?
  • A: Sometimes used as an adjunct to antidepressants; check for MAOI interactions and CYP3A4 issues and monitor closely.
  • Q: How are side effects managed?
  • A: Take with food if nausea occurs, split doses for dizziness, and report any persistent or severe effects to your clinician.

Registration and regulation

MHRA approval process

Is buspirone regulated in the UK?

Buspirone is licensed in the UK and is prescription only.

Product licences list the manufacturer and approved indications; prescribers should adhere to licences or document off‑label rationale and patient consent when deviating.

Report suspected adverse events to the MHRA Yellow Card scheme.

NHS prescribing framework

  • Prescriptions are issued by GPs, specialists or private psychiatrists and electronic prescribing is standard.
  • Community pharmacists perform clinical checks at dispensing including interaction screens and counselling.
  • Buspirone is not a controlled drug, but normal safety checks and record‑keeping are required.
  • Regulatory responsibilities include reporting adverse events, maintaining accurate records and obtaining informed consent for off‑label use.

Storage, handling and guidelines for proper use (UK household focus)

UK household storage (cold/damp climate)

How should patients store buspirone at home?

Store at controlled room temperature, typically 20–25°C, away from moisture and direct sunlight.

Keep tablets in their original packaging to maintain stability and product information.

Advise patients in humid UK homes to keep tablets in a dry cupboard rather than the bathroom.

Keep all medicines out of reach and sight of children.

UK pharmacist counselling style and NHS patient safety advice

What should a pharmacist tell a patient collecting buspirone?

  • Explain the expected onset (2–4 weeks) and reinforce that buspirone is not for immediate relief of panic.
  • Discuss common side effects and simple steps to manage them, such as taking with food for nausea.
  • Review other medicines with the patient and highlight interactions with alcohol and strong CYP3A4 inhibitors.
  • Provide missed dose advice and emphasise not to double doses.
  • Encourage follow‑up with the prescriber and reporting of adverse effects to the MHRA Yellow Card scheme.

Delivery across the United Kingdom

City Region Delivery Time
London England 5‑7 days
Birmingham West Midlands 5‑7 days
Manchester Greater Manchester 5‑7 days
Glasgow Scotland 5‑7 days
Liverpool Merseyside 5‑7 days
Leeds West Yorkshire 5‑7 days
Sheffield South Yorkshire 5‑9 days
Bristol South West England 5‑7 days
Edinburgh Scotland 5‑7 days
Cardiff Wales 5‑7 days
Newcastle Upon Tyne Tyne and Wear 5‑9 days
Belfast Northern Ireland 5‑7 days
Nottingham Nottinghamshire 5‑9 days

Related products